Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib

PURPOSE: EphA2 is an attractive therapeutic target due to its diverse roles in cancer growth and progression. Dasatinib is a multi-kinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are ne...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Huang, Jie, Hu, Wei, Bottsford-Miller, Justin, Liu, Tao, Han, Hee Dong, Zand, Behrouz, Pradeep, Sunila, Roh, Ju-Won, Thanapprapasr, Duangmani, Dalton, Heather J., Pecot, Chad V., Rupaimoole, Rajesh, Lu, Chunhua, Fellman, Bryan, Urbauer, Diana, Kang, Yu, Jennings, Nicholas B., Huang, Li, Deavers, Michael T., Broaddus, Russell, Coleman, Robert L., Sood, Anil K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3975695/
https://ncbi.nlm.nih.gov/pubmed/24486585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2141
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller